IN THE CLAIMS

1. **(Currently Amended)** An oral formulation comprising:

a drug;

sucrose acetate isobutyrate (SAIB);

a network former **selected from the group consisting of a cellulose acetate, cellulose acetate butyrate, cellulose acetate phthalate, a hydrogel, silicon dioxide, and an ion exchange resin**;

a rheology modifier selected from the group consisting of isopropyl myristate (IPM), ethyl oleate, dimethyl phthalate, benzyl benzoate, and a caprylic/capric triglyceride; and

a solvent.

2.-79. (Cancelled)

80. (Previously Presented) The oral formulation of claim 1, wherein the formulation comprises from about 1 to about 8.6 weight percent of the network former.

81. (Previously Presented) The oral formulation of claim 1, wherein the network former comprises a cellulose acetate butyrate (CAB).

82. (Previously Presented) The oral formulation of claim 81, wherein the CAB has a butyryl content range from 17 to 38 weight percent, an acetyl content range from 13 to 30 weight percent, and a hydroxyl content range from 0.8 to 1.7 weight percent .

83. (Previously Presented) The oral formulation of claim 1, wherein the formulation comprises from about 20 to about 50 weight percent of the solvent.

84. (Previously Presented) The oral formulation of claim 83, wherein the solvent is selected from the group consisting of ethyl lactate (EL), triacetin, dimethyl sulfoxide (DMSO), propylene carbonate, N-methylpyrrolidone (NMP), ethyl alcohol, benzyl alcohol, glycofurol, alpha-tocoperol, isopropyl alcohol, diethyl phthalate, polyethylene glycol 400 (PEG 400), triethyl citrate, benzyl benzoate, and a caprylic/capric triglyceride.

85. (Previously Presented) The oral formulation of claim 1, wherein the rheology modifier is IPM.

86. (Previously Presented) The oral formulation of claim 1, wherein the solvent is triacetin.

87. (**Canceled**)

88. (Previously Presented) The oral formulation of claim 1, wherein the formulation comprises:

from about 0.01 to about 75 weight percent of the network former;

from about 1 to about 75 weight percent of the rheology modifier; and

from about 0.01 to about 75 weight percent of the solvent.

89. (Previously Presented) The oral formulation of claim 1, wherein the drug is selected from the group consisting of an opioid, a central nervous system (CNS) depressant and a stimulant.

90. (Previously Presented) The oral formulation of claim 89, wherein the drug is an opioid.

91. (Previously Presented) The oral formulation of claim 89, wherein the drug is oxycodone, hydrocodone, oxymorphone or hydromorphone.

92. (Previously Presented) The oral formulation of claim 89, wherein the drug is oxycodone.

93. (Previously Presented) The oral formulation of claim 89, wherein the drug is a stimulant.

94. (Previously Presented) The oral formulation of claim 93, wherein the drug is dextroamphetamine or methylphenidate.

95. (Previously Presented) An oral dosage form comprising the formulation of claim 1, wherein the formulation is contained in a capsule.

96. (Previously Presented) The oral dosage form of claim 95, wherein the capsule is a gelatin capsule.

97. (**Currently Amended**) An oral formulation comprising:

a drug;

sucrose acetate isobutyrate (SAIB);

a network former **selected from the group consisting of a cellulose acetate, cellulose acetate butyrate, cellulose acetate phthalate, a hydrogel, silicon dioxide, and an ion exchange resin**;

a rheology modifier; and

a solvent in which the network former is soluble.

98. (Previously Presented) The oral formulation of claim 97, wherein the network former comprises a cellulose acetate butyrate or cellulose acetate phthalate.

99. (Previously Presented) The oral formulation of claim 97, wherein the network former is cellulose acetate butyrate (CAB).

100. (Previously Presented) The oral formulation of claim 99, wherein the CAB has a butyryl content range from 17 to 38 weight percent, an acetyl content range from 13 to 30 weight percent, and a hydroxyl content range from 0.8 to 1.7 weight percent.

101. (Previously Presented) The oral formulation of claim 97, wherein the rheology modifier is selected from the group consisting of isopropyl myristate (IPM), ethyl oleate, triethyl citrate, dimethyl phthalate, benzyl benzoate, and a caprylic/capric triglyceride.

102. (Previously Presented) The oral formulation of claim 97, wherein the rheology modifier is IPM.

103. (Previously Presented) The oral formulation of claim 97, wherein the solvent is selected from the group consisting of ethyl lactate (EL), triacetin, dimethyl sulfoxide (DMSO), propylene carbonate, N-methylpyrrolidone (NMP), ethyl alcohol, benzyl alcohol, glycofurol, alpha-tocoperol, isopropyl alcohol, diethyl phthalate, polyethylene glycol 400 (PEG 400), triethyl citrate, benzyl benzoate, and a caprylic/capric triglyceride.

104. (Previously Presented) The oral formulation of claim 97, wherein the solvent is triacetin.

105. (Previously Presented) The oral formulation of claim 97, wherein the drug is selected from the group consisting of an opioid, a central nervous system (CNS) depressant and a stimulant.

106. (Previously Presented) The oral formulation of claim 97, wherein the drug is an opioid.

107. (Previously Presented) The oral formulation of claim 106, wherein the drug is oxycodone, hydrocodone, oxymorphone or hydromorphone.

108. (Previously Presented) The oral formulation of claim 106, wherein the drug is oxycodone.

109. (Previously Presented) The oral formulation of claim 97, wherein the drug is a stimulant.

110. (Previously Presented) The oral formulation of claim 97, wherein the drug is dextroamphetamine or methylphenidate.

111. (Previously Presented) An oral dosage form comprising the formulation of claim 97, wherein the formulation is contained in a capsule.

112. (Previously Presented) The oral dosage form of claim 111, wherein the capsule is a gelatin capsule.

113. (**Currently Amended**) An oral formulation comprising:

a drug;

sucrose acetate isobutyrate (SAIB);

a network former **selected from the group consisting of a cellulose acetate, cellulose acetate butyrate, cellulose acetate phthalate, a hydrogel, silicon dioxide, and an ion exchange resin**;

a rheology modifier selected from the group consisting of isopropyl myristate (IPM), ethyl oleate, dimethyl phthalate, benzyl benzoate, and a caprylic/capric triglyceride; and

a solvent in which the network former is soluble.

114. (Previously Presented) The oral formulation of claim 113, wherein the network former comprises a cellulose acetate butyrate or cellulose acetate phthalate.

115. (Previously Presented) The oral formulation of claim 113, wherein the network former comprises cellulose acetate butyrate (CAB).

116. (Previously Presented) The oral formulation of claim 113, wherein the CAB has a butyryl content range from 17 to 38 weight percent, an acetyl content range from 13 to 30 weight percent, and a hydroxyl content range from 0.8 to 1.7 weight percent.

117. (Previously Presented) The oral formulation of claim 113, wherein the rheology modifier is IPM.

118. (Previously Presented) The oral formulation of claim 113, wherein the solvent is triacetin.

119. (Previously Presented) The oral formulation of claim 113, wherein the drug is selected from the group consisting of an opioid, a central nervous system (CNS) depressant and a stimulant.

120. (Previously Presented) The oral formulation of claim 113, wherein the drug is an opioid.

121. (Previously Presented) The oral formulation of claim 120, wherein the drug is oxycodone, hydrocodone, oxymorphone or hydromorphone.

122. (Previously Presented) The oral formulation of claim 120, wherein the drug is oxycodone.

123. (Previously Presented) The oral formulation of claim 113, wherein the drug is a CNS stimulant.

124. (Previously Presented) The oral formulation of claim 113, wherein the drug is dextroamphetamine or methylphenidate.

125. (Previously Presented) An oral dosage form comprising the formulation of claim 113, wherein the formulation is contained in a capsule.

126. (Previously Presented) The oral dosage form of claim 125, wherein the capsule is a gelatin capsule.